Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 6/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL816053 | 0.97 | MAPT (0.47) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL815808 | 0.94 | MAPT (0.46) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL815896 | 0.92 | MAPT (0.49) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL13255771 | 0.91 | HDAC6 (0.54) | KMT2AMEN1CA12CA9HDAC6 | |
| SCHEMBL816382 | 0.91 | THRA (0.40) | MAPTKMT2ACYP3A4 | |
| SCHEMBL24086194 | 0.91 | MAPT (0.52) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL15590581 | 0.91 | MAPT (0.59) | MAPTKMT2AMEN1CYP3A4TDP1 | |
| SCHEMBL20195755 | 0.90 | MAPT (0.42) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL30599638 | 0.90 | MAPT (0.51) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL1951824 | 0.90 | MAPT (0.51) | MAPTKMT2AMEN1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2695930-B1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE, NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE | DAINIPPON INK & CHEMICALS (JP) | 2019-09-11 | — | — | EP | disclosed |
| EP-2261201-B1 | TRIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | DAINIPPON INK & CHEMICALS (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9475991-B2 | Polymerizable liquid crystal composition, polarized light-emitting coating material, novel naphtholactam derivative novel coumarin derivative, novel nile red derivative, and novel anthracene derivative | ADEKA CORPORATION (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475991-B2 | Polymerizable liquid crystal composition, polarized light-emitting coating material, novel naphtholactam derivative novel coumarin derivative, novel nile red derivative, and novel anthracene derivative | ADEKA CORPORATION (JP) | 2016-10-25 | — | — | US | disclosed |
| US-8663497-B2 | Liquid crystal composition comprising polymerizable compound, and liquid crystal display element using said liquid crystal composition | ADEKA CORPORATION (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8663497-B2 | Liquid crystal composition comprising polymerizable compound, and liquid crystal display element using said liquid crystal composition | ADEKA CORPORATION (JP) | 2014-03-04 | — | — | US | disclosed |
| EP-2695930-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE, NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE | Adeka Corporation (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20130334461-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE | ADEKA CORPORATION (JP) | 2013-12-19 | — | — | US | disclosed |
| US-20130334461-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE | ADEKA CORPORATION (JP) | 2013-12-19 | — | — | US | disclosed |
| EP-2502973-A1 | LIQUID CRYSTAL COMPOSITION COMPRISING POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAID LIQUID CRYSTAL COMPOSITION | Adeka Corporation (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20120200794-A1 | LIQUID CRYSTAL COMPOSITION COMPRISING POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAID LIQUID CRYSTAL COMPOSITION | ADEKA CORPORATION (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120200794-A1 | LIQUID CRYSTAL COMPOSITION COMPRISING POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAID LIQUID CRYSTAL COMPOSITION | ADEKA CORPORATION (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8197710-B2 | Polymerizable compound and polymerizable composition | ADEKA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8057701-B2 | Trifunctional (meth)acrylate compound and polymerizable composition containing same | ADEKA CORPORATION (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20110037025-A1 | TRIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING SAME | ADEKA CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110037025-A1 | TRIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING SAME | ADEKA CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20100294990-A1 | POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION | ADEKA CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100294990-A1 | POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION | PYM1, SCO2, ZYX | MAPT 2010/4885KMT2A 1150/4885MEN1 255/4885 |
| US-20110037025-A1 | TRIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING SAME | PYM1, MT-CO1, MAT1A | MAPT 1180/4885KMT2A 1215/4885MEN1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.